In an effort to develop next-generation treatments for cystinuria, researchers at Vanderbilt University and Tennessee Valley Health Services have used a non-viral piggyBac transposon approach to insert the Slc3a1 gene into one kidney of mice lacking the endogenous gene, which services as a model of type A cystinuria.
Memo Therapeutics AG is laying plans to advance its BK polyomavirus neutralizing monoclonal antibody potravitug into phase III development after reporting positive phase II results in treating infections in immunocompromised kidney transplant patients.
Hypertensive nephropathy is a major complication of hypertension characterized by inflammation and fibrosis in the kidneys. Recent findings have suggested that agrin may play a critical role in some tissue types such as in the heart or skeletal muscle.
Launched out of 5AM Ventures’ 4:59 Initiative, Renasant Bio Inc. has secured $54.5 million in seed funding to support development of treatments for autosomal dominant polycystic kidney disease (ADPKD), a genetic disease caused by mutations in the PKD1 and PKD2 genes, which encode polycystin proteins PC1 and PC2 that come together to form a calcium ion channel vital for kidney function.
Ube Corp. and Galts Pharma Co. Ltd., a venture company from Kumamoto University, have signed an agreement giving Galts exclusive worldwide rights to develop, manufacture and market UD-051 (GP-051), a compound discovered through joint research by Ube and Kumamoto University.
Hemolytic uremic syndrome (HUS) is a severe condition that primarily affects young children and typically occurs after a gastrointestinal infection with Shiga toxin 2 (Stx2)-producing Escherichia coli (STEC).
Renasant Bio Inc. has launched to develop new disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the primary genetic cause of end-stage renal failure. The $54.5 million in seed funding the company has secured will support advancement of its lead corrector program and ongoing discovery efforts for the company’s first-in-class potentiator program.
A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel. The results came from two arms of the study, each with its own treatment regime. The market heartily took to the results as the company’s stock (NASDAQ:PROK) closed 515% upward at $3.73 per share after starting the day under $1 each.
Chinese researchers are preparing the details for the publication of another scientific milestone, the creation of a chimera with a human heart and a kidney developed from human stem cells in pig embryos.
RSS
